<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03020797</url>
  </required_header>
  <id_info>
    <org_study_id>Eisai-01</org_study_id>
    <nct_id>NCT03020797</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot trial to test perampanel (Fycompa; Eisai, Inc.) in ALS patients. The
      investigators will focus on safety and preliminary signs of efficacy. Perampanel is approved
      by the FDA for treatment of seizures in patients with epilepsy. In this study, perampanel
      will be used off-label for adults with ALS at an oral medication dose on the low end of the
      recommended dose range for epilepsy. This study will consist of two treatments arms:
      perampanel and matching placebo randomized at a 1:1 ratio. Subjects will receive medication
      for 9 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by change in ALSFRS-R score (ALS functional rating scale-revised);</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>perampanel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>perampanel 2mg QD for 2 weeks perampanel 4mg QD for 2 weeks perampanel 6mg QD for 2 weeks perampanel 8mg QD for 30 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 1 tablet QD for 2 weeks placebo 2 tablets QD for 2 weeks placebo 3 tablets QD for 2 weeks placebo 4 tablets QD for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <arm_group_label>perampanel</arm_group_label>
    <other_name>Fycompa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosis of ALS

          2. first clinical weakness within past 3 years

          3. slow vital capacity &gt;= 60% of predicted within 1 month of treatment

          4. may be on stable dose of riluzole for at least 30 days, or otherwise agree to not
             initiate riluzole for duration of the trial

          5. can travel to Stony Brook to receive medical care

          6. must have a monitor who can be contacted at regular intervals to report on subject's
             clinical/psychiatric status

        Exclusion Criteria:

          1. use of tracheostomy or mechanical ventilation within last 3 months

          2. hepatic insufficiency or abnormal liver function

          3. renal insufficiency

          4. clinically significant psychiatric disorder

          5. history of malignancy &lt; 5 years prior to entry

          6. history of HIV, clinically significant chronic hepatitis, or other active infection

          7. history of stomach or intestinal surgery or condition that could interfere with
             absorption, distribution, metabolism or secretion of study drug

          8. history of alcohol or substance abuse within 3 months prior to entry (subjects will be
             instructed to refrain from alcohol during the study)

          9. use of strong cytochrome P4503A inhibitors or inducers, anticonvulsants or other drugs
             known to interact strongly with perampanel.

         10. pregnancy or lactation

         11. clinically significant medical condition (other than ALS) that would pose a risk to
             the subject if they were to participate

         12. know hypersensitivity to perampanel

         13. currently participating, or has participated in a study with an investigation or
             marketed compound within 3 months of entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diana Kaell, BA</last_name>
    <phone>631-444-7832</phone>
    <email>diana.kaell@stonybrookmedicine.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nurcan Gursoy, MD</last_name>
    <phone>631-444-2599</phone>
    <email>nurcan.gursoy@stonybrookmedicine.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Kaell, BA</last_name>
      <phone>631-444-7832</phone>
      <email>diana.kaell@stonybrookmedicine.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nurcan Gursoy, MD</last_name>
      <phone>631-444-2599</phone>
      <email>nurcan.gursoy@stonybrookmedicine.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dennis Choi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rahman Pourmand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Nurcan Gursoy</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

